# MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial

> **NCT07381699** · PHASE2 · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)

## Interventions

- **DRUG:** Becotatug Vedotin and Pucotenlimab

## Key facts

- **NCT ID:** NCT07381699
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2030-02-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07381699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07381699, "MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07381699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*